NapaJen Pharma Overview
- Year Founded
-
2004
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
2ndary - Private
- Investors
-
5
NapaJen Pharma General Information
Description
Developer of nucleic-acid drugs designed to positively impact the major challenge of side effects and toxicity in the pharmaceutical industry. The company's drugs are complexed and protected from degradation enzymes while being delivered to immature dendritic cells or macrophages, enabling physicians to offer a safe and productive treatment to their patients for unmet medical needs.
Contact Information
Website
www.napajen.comCorporate Office
- 1201 3rd Avenue
- Suite 2200
- Seattle, WA 98101
- United States
Corporate Office
- 1201 3rd Avenue
- Suite 2200
- Seattle, WA 98101
- United States
NapaJen Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Secondary Transaction - Private | 18-Mar-2024 | Completed | Clinical Trials - Phase 1 | |||
| 6. Later Stage VC | 14-Sep-2021 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC (Series C) | 09-Jan-2019 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC (Series B1) | 14-May-2018 | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC (Series B) | 21-Nov-2016 | Completed | Startup | |||
| 2. Later Stage VC (Series A1) | 03-Feb-2014 | $9M | $11.4M | Completed | Startup | |
| 1. Later Stage VC (Series A) | 19-Sep-2012 | $2.38M | $2.38M | Completed | Startup |
NapaJen Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
NapaJen Pharma Comparisons
Industry
Financing
Details
NapaJen Pharma Competitors (32)
One of NapaJen Pharma’s 32 competitors is Ambagon Therapeutics, a Venture Capital-Backed company based in Eindhoven, Netherlands.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ambagon Therapeutics | Venture Capital-Backed | Eindhoven, Netherlands | ||||
| Ncardia | Venture Capital-Backed | Leiden, Netherlands | ||||
| Maze Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Alexion | Formerly VC-backed | Boston, MA | ||||
| Lisata Therapeutics | Corporation | Basking Ridge, NJ |
NapaJen Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
NapaJen Pharma Patents
NapaJen Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4227416-A1 | Homogeneous beta-1,3-glucan/nucleic acid complex and use thereof | Inactive | 09-Oct-2020 | ||
| EP-4227416-A4 | Homogeneous beta-1,3-glucan/nucleic acid complex and use thereof | Inactive | 09-Oct-2020 | ||
| US-20230365966-A1 | Homogeneous beta-1,3-glucan/nucleic acid complexes and use thereof | Pending | 09-Oct-2020 | ||
| WO-2022075460-A1 | Homogeneous β-1,3-glucan/nucleic acid complex and use thereof | Inactive | 09-Oct-2020 | ||
| JP-7863786-B2 | Homogeneous β-1,3-glucan/nucleic acid complex, and its applications | Active | 09-Oct-2020 | C12N15/113 |
NapaJen Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
NapaJen Pharma Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| KNC Laboratories | Corporation | Minority | ||
| Remiges Ventures | Venture Capital | Minority | ||
| Technology Seed Incubation | Venture Capital | Minority | ||
| P&E Directions | Corporation | Minority | ||
| Mitsui Global Investment | Venture Capital | Minority |
NapaJen Pharma FAQs
-
When was NapaJen Pharma founded?
NapaJen Pharma was founded in 2004.
-
Where is NapaJen Pharma headquartered?
NapaJen Pharma is headquartered in Seattle, WA.
-
What is the size of NapaJen Pharma?
NapaJen Pharma has 3 total employees.
-
What industry is NapaJen Pharma in?
NapaJen Pharma’s primary industry is Drug Discovery.
-
Is NapaJen Pharma a private or public company?
NapaJen Pharma is a Private company.
-
What is NapaJen Pharma’s current revenue?
The current revenue for NapaJen Pharma is .
-
How much funding has NapaJen Pharma raised over time?
NapaJen Pharma has raised $40.3M.
-
Who are NapaJen Pharma’s investors?
KNC Laboratories, Remiges Ventures, Technology Seed Incubation, P&E Directions, and Mitsui Global Investment have invested in NapaJen Pharma.
-
Who are NapaJen Pharma’s competitors?
Ambagon Therapeutics, Ncardia, Maze Therapeutics, Alexion, and Lisata Therapeutics are some of the 32 competitors of NapaJen Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
